Brainstorm Cell Therapeutics Inc.
BCLI
$0.69
$0.00-0.29%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.78M | 5.85M | 6.71M | 7.31M | 7.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.95M | 10.90M | 11.90M | 12.31M | 11.69M |
| Operating Income | -9.95M | -10.90M | -11.90M | -12.31M | -11.69M |
| Income Before Tax | -10.31M | -10.85M | -11.45M | -11.09M | -11.62M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.31 | -10.85 | -11.45 | -11.09 | -11.62 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.31M | -10.85M | -11.45M | -11.09M | -11.62M |
| EBIT | -9.95M | -10.90M | -11.90M | -12.31M | -11.69M |
| EBITDA | -9.75M | -10.69M | -11.68M | -12.08M | -11.45M |
| EPS Basic | -1.20 | -1.50 | -1.82 | -2.02 | -2.35 |
| Normalized Basic EPS | -0.75 | -0.94 | -1.14 | -1.26 | -1.47 |
| EPS Diluted | -1.20 | -1.50 | -1.82 | -2.02 | -2.35 |
| Normalized Diluted EPS | -0.75 | -0.94 | -1.14 | -1.26 | -1.47 |
| Average Basic Shares Outstanding | 37.02M | 31.68M | 25.98M | 22.11M | 20.08M |
| Average Diluted Shares Outstanding | 37.02M | 31.68M | 25.98M | 22.11M | 20.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |